scholarly journals Stem Cell Therapy in Myocardial Infarction Clinical Point of View and the Results of the REANIMA Study (REgenerAtion of Myocardium with boNe Marrow Mononuclear Cells in MyocArdial Infarction)

10.5772/17700 ◽  
2011 ◽  
Author(s):  
Slobodan Obradovic ◽  
Bela Balint ◽  
Zoran Trifunovic
Keyword(s):  
Myocardial Infarction ◽  
Bone Marrow ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mononuclear Cells ◽  
Point Of View ◽  
Bone Marrow Mononuclear Cells ◽  
Clinical Point

scholarly journals Điều trị chấn thương sọ não cấp tính bằng ghép tế bào gốc tự thân tại Bệnh viện Trung ương Huế

2020 ◽  
Author(s):  
Duy Thăng Nguyễn
Keyword(s):  
Traumatic Brain Injury ◽  
Stem Cells ◽  
Bone Marrow ◽  
Stem Cell ◽  
Brain Injury ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mononuclear Cells ◽  
Control Group ◽  
Acute Traumatic Brain Injury

TREATING ACUTE TRAUMATIC BRAIN INJURY BY USING AUTOLOGOUS BONE MARROW DERIVED STEM CELLS AT HUE CENTRAL HOSPITAL The number of acute traumatic injuries caused by accidents has been increasing in recent years, leading to death or serious complications in cognitive behavior or social function. Few pre-clinical studies around the world have shown the ablity of stem cells in neuroprotection. Therefore, we apply autologous stem cells transplants in two acute traumatic brain injury patients to evaluate the effectiveness of stem cell therapy. Method: Three male patients aged 23 and 49 years with a postresuscitation Glasgow Coma Scale of 6 and 8 were treated with autologous mononuclear cells delivered intravenously within 2-3 hours after bone marrow harvesting, mesenchymal stem cells were isolated and expanded in culture before the system administrating through vein after 7-10 days. To determine the safety of the procedure, systemic and cerebral hemodynamics were monitored during bone marrow harvest; infusion-related toxicity was determined by hepatic enzymes, and renal function. Result and conclusion: There were no significant changes in liver, kidney and hematological criteria. BI and Glasgow indexes increased significantly compared to the control group. There was no abnormal complication within 4-6 weeks after cell transplantation. Autologous stem cell therapy is safe and effective for patients with acute brain injury. Keywords: Stem cells; Mesenchymal stem cell; Bone marrow; Acute traumatic brain injury

scholarly journals Influence of intracoronary injections of bone-marrow-derived mononuclear cells on large myocardial infarction outcome: Quantum of initial necrosis is the key

2009 ◽  
Vol 66 (12) ◽  
pp. 998-1004 ◽  
Author(s):  
Slobodan Obradovic ◽  
Bela Balint ◽  
Radoslav Romanovic ◽  
Zoran Trifunovic ◽  
Sinisa Rusovic ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Bone Marrow ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Autologous Bone Marrow ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Infarction Size ◽  
Autologous Bone

Background/Aim. Autologous bone-marrow-derived intracoronary injection of mononuclear cells (MNC) modestly improved left ventricular ejection fraction (LVEF) in the selected patients after acute ST elevation myocardial infarction (STEMI). Major determinants of stem cell therapy outcome in the subacute phase of STEMI still remain unknown. Therefore, the aim of this study was to determine modifying factors for the outcome of stem cell therapy after STEMI. Methods. Eighteen patients in the stem cell therapy group and 24 patients in the control group with the successfully reperfused first large STEMI (LVEF ? 40%) were enrolled in the study. The stem cell group was submitted to autologous bone-marrow-derived MNC injection between 7-12 days after MI. Left ventricular ejection fraction and infarction size at baseline and after 4 months were determined by echocardiography and scintigraphy examination. Age, pain onset to reperfusion time, admission glycemia, maximum lactate dehydrogenase (LDH) activity and C-reactive protein level, baseline LVEF and infarction size, and the number of MNC injected were compared between patients with and without significant improvement of LVEF and decrease of myocardial infarct size after 4 months. Results. In the stem cell group, patients with the improvement of LVEF for more than 5.1% had significantly lower levels of LDH than patients without such improvement (1689 ? 139 vs 2133 ? 215 IU/L, p < 0.001) and lower baseline infarction size on scintigraphy (26.7 ? 5.2 vs 34.9 ? 3.7%, p < 0.001). Such dependence was not found in the control group. Conclusion. In the patients with first large STEMI intracoronary injection of autologous bone-marrow-derived MNC leads to the significant decrease of myocardial infarction size but not the significant improvement of LVEF after four months. Higher serum LDH levels after STEMI and very large baseline infarction size are predictors of failure of stem cell therapy in our group of STEMI patients.

scholarly journals Stem cells for myocardial repair

2010 ◽  
Vol 104 (07) ◽  
pp. 6-12 ◽  
Author(s):  
Chung-Wah Siu ◽  
Song-Yan Liao ◽  
Yuan Liu ◽  
Qizhou Lian ◽  
Hung-Fat Tse
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Clinical Trials ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Myocardial Ischaemia ◽  
Bone Marrow Derived Cells

SummaryThere is a growing interest in the clinical application for stem cell as a novel therapy for treatment of acute myocardial infarction and chronic myocardial ischaemia. The initial premise is the transplanted exogenous stem cells can engraft and integrate with host myocardium for cardiac regeneration. However, recent experimental studies suggest that multiple mechanisms, including remodelling of extracellular matrix, enhancement of neovascularisation and recruitment of endogenous stem cells are more likely to contribute to the beneficial effects of stem cell therapy that direct trans-differentiation of stem cells into functional myocardium. Among different potential cell sources, bone marrow-derived cells and skeletal myoblasts have been tested in pilot clinical trials. Phase I/II randomised controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be safe and feasible strategies for treatment of acute myocardial infarction as well as chronic myocardial ischaemia. In addition, these studies show a modest, but significant improvement in left ventricular ejection fraction and clinical status of patients after cell transplantation. Nevertheless, most of these studies included a relatively small sample size (<200) and short duration of follow-up (<6 months), and the clinical efficacy of stem cell therapy need to be confirmed by future clinical trials. Furthermore, the optimal timing, cell types and mode of delivery need to be addressed, and strategies to improve cell survival and engraftment should also be developed to overcome the potential hurdles related to cell-based therapy.

Sign in / Sign up

Export Citation Format

Share Document